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Abstract
The immune suppressive protein CTLA-4 is constitutively expressed by Tregs and induced
in effector T cells upon activation. Its crucial role in adaptive immunity is apparent from the
fatal autoimmune pathology seen in CTLA-4 knockout mice. However, little is known
regarding factors that regulate CTLA-4 expression and their effect upon its function to
remove CD80 and CD86 from antigen presenting cells by transendocytosis. Th17 cells are
emerging as significant players in autoimmunity as well as other diseases. Therefore, in
this study we have examined the effects of Th17 polarising conditions on CTLA-4 expres-
sion and function in human T cells and show that Th17 conditions can suppress the
expression of CTLA-4 and its transendocytic function. In contrast to Th17 cells, vitamin D
is inversely associated with autoimmune disease. We have previously shown a striking
ability of 1,25 dihydroxyvitamin D3 (1,25(OH)2D3) to enhance CTLA-4, however, its effects
upon B7 transendocytosis and its activity in the context of inflammation remained
unknown. Here we show that induction of CTLA-4 by 1,25(OH)2D3 can actually be
enhanced in the presence of Th17 polarising cytokines. Furthermore, its transendocytic
function was maintained such that T cells generated in the presence of Th17 conditions
and 1,25(OH)2D3 were highly effective at capturing CTLA-4 ligands from antigen present-
ing cells and suppressing T cell division. Taken together, these data reveal an inhibitory
effect of Th17 polarising conditions upon CTLA-4-mediated regulation and show that 1,25
(OH)2D3 counteracts this effect. Given the importance of CTLA-4-mediated suppression in
the control of autoimmune diseases, our novel data highlight the importance of vitamin D in
inflammatory settings.
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Introduction
CTLA-4 is a critical suppressive protein that is expressed constitutively by regulatory T cells
(Treg) and is induced on conventional T cells following activation [1–4]. It functions to
restrain inappropriate activation of autoreactive T cells and to restore T cell homeostasis fol-
lowing activation. This crucial regulatory role of CTLA-4 is evident from the lethal lympho-
proliferative phenotype of CTLA-4 knockout mice [5, 6]. Recently, we and others observed
CTLA-4 genetic variants that affected the level of CTLA-4 protein in autoimmunity and
immunodeficiency, which indicates the importance of CTLA-4 expression in controlling
human disease [7, 8]. Understanding how CTLA-4 expression is regulated therefore holds
potential for therapeutic advances in conditions characterised by inappropriate or excessive
T cell activation. Numerous studies have investigated the mechanisms by which CTLA-4
functions, leading to a range of proposed models [9–11]. An important feature of CTLA-4
biology is its internalisation and cycling back to the plasma membrane as well as its traffick-
ing to lysosomes for degradation [12–14]. Consistent with this biology, we recently observed
that CTLA-4 is able to remove its ligands, CD86 and CD80, from APCs and target them for
degradation in a process termed transendocytsosis [15]. In this way, CTLA-4 reduces the
availability of its shared ligands for CD28 co-stimulation in a quantitative manner that
depends on the level of CTLA-4 expression. Surprisingly, despite the crucial role of CTLA-4
in immune regulation, relatively little is known about how its expression level and transendo-
cytic activity are controlled, including the influence of environmental factors or the cytokine
milieu.
Th17 cells, which play an important role in the clearance of certain extracellular and intra-
cellular pathogens [16, 17], are differentiated under inflammatory cytokine conditions and
their dysregulation contributes to the pathology of a range of autoimmune diseases [18–20].
Their differentiation is intriguing since it is closely related to that of Treg through the common
involvement of TGFβ [21, 22] with cytokines such as IL-1β, IL-6 and IL-23 promoting a Th17
outcome in humans [23, 24]. The relationship between inflammatory Th17 conditions and
CTLA-4 expression is currently not well understood. In contrast, vitamin D is emerging as an
important regulator of inflammatory responses. Indeed, low vitamin D status is associated with
an increased risk of inflammatory diseases, including multiple sclerosis, type 1 diabetes, rheu-
matoid arthritis and systemic lupus erythematosis (reviewed in [25–29]). Furthermore, vitamin
D supplementation in mouse models of autoimmunity has suggested both prophylactic and
therapeutic benefit [30–33].
We have shown that production of Th17-related cytokines is inhibited by vitamin D whilst
regulatory markers, including CTLA-4, Foxp3 and IL-10, are increased [34] suggesting that
vitamin D antagonises inflammatory outcomes and promotes regulation. In order to achieve a
regulatory effect in an autoimmune setting, vitamin D would need to be effective within an
inflammatory milieu. We therefore sought to determine the impact of such an environment on
the expression and function of CTLA-4. We show that pro-Th17 cytokines substantially reduce
CTLA-4 expression and function. However, even under Th17 polarizing conditions, vitamin D
continues to drive upregulation of CTLA-4, generating T cells with CTLA-4-dependent regula-
tory function.
Materials and Methods
This study was approved by the University of Birmingham Ethics Committee and given
approval number ERN_14–0446.
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Cell isolation and culture
PBMCs were isolated by Ficoll gradient centrifugation from fresh leukocyte reduction system
cones provided by the National Blood Service, Birmingham, UK. PBMCs were washed twice
with PBS and twice with MACS buffer (0.5% BSA, 2 mM EDTA in PBS) and re-suspended at 1
x 108 cells/ml for magnetic separation. Conventional CD4+CD25- T cells and CD14+ mono-
cytes were enriched by negative selection using cell separation reagents (StemCell Technolo-
gies). Greater than 95% purity was obtained as assessed by flow cytometry.
T cells were cultured in serum free medium (CellGenix) supplemented with 50U/ml Penicil-
lin and Streptomycin (Gibco, Life Technologies). To assess the effect of cytokines and 1,25
(OH)2D3 upon their phenotype, T cells were stimulated with antiCD3CD28 Dynabeads (Life-
Technologies) at a ratio of 1 bead: 4 T cells in the presence of recombinant cytokines and sup-
plements as described in the figure legends. Supplements were added at the following
concentrations: IL-1β (10ng/ml, Peprotech), IL-6 (20ng/ml, Immunotools), IL-23 (10ng/ml R
and D Systems), TGFβ (1ng/ml, R and D Systems), 1,25(OH)2D3 (10nM, Sigma Alrich) and
anti-human CTLA-4 (ticilimumab) (20μg/ml, a generous gift from Pfizer). The carrier for 1,25
(OH)2D3 was ethanol. It was diluted 1 in 1000 (v/v) into the culture. This concentration did
not affect the measured outcomes. For all other reagents the vehicle was PBS.
Monocyte derived dendritic cells (DCs) were cultured from monocytes in RPMI containing
10% FBS (Biosera), 50U/ml Penicillin and Streptomycin, 200μM glutamine (Life Technologies)
(RPMI-FBS) and supplemented with GM-CSF (800U/ml, Peprotech) and IL-4 (500U/ml
Peprotech). 1x106 cells were plated per well of a 24 well culture plate. At two to three days, cells
were supplemented with fresh medium containing IL-4 and GM-CSF and cultured for a further
six or seven days before use. DCs were CD11C+, CD14- and up-regulated CD86, CD80, CD40
and HLA-DR upon maturation with LPS (100ng/ml (Sigma Aldrich). All cells were cultured at
37°C, 95% humidity and 5% CO2.
Cell labelling
For some experiments, T cells were labelled with cell trace proliferation dyes, CFDA-SE or cell
trace violet (Molecular probes, Life Technologies). Cells were washed two times with PBS and
re-suspended in cell proliferation dye. CFDA-SE labelling was performed for 10 minutes at
room temperature after which cells were washed three times in RPMI-FBS. For cell trace violet
labelling T cells were labelled with cell trace violet for 20 minutes at 37°C. 10% FBS RPMI was
added to quench the labelling. After incubation for 5 minutes at 37°C and centrifugation at
room temperature, cells were washed a further two times with 10% FBS RPMI.
Flow cytometry
Dead cells were labelled with near-IR LIVE/DEAD fixable dead cell stain (Molecular Probes,
Life Technologies) before fixation. For analysis of total CTLA-4, Foxp3 and CD25, cells were
fixed, permeabilised and stained with ebioscience Foxp3 staining buffers according to the
manufacturer’s instructions. For analysis of cytokine expression, cells were re-stimulated with
PMA (50ng/ml), and ionomycin (1μM) for 5 hours, with Brefeldin A (10μg/ml) present dur-
ing the last 4 hours (all from Sigma Aldrich). Cells were fixed with 3% paraformaldehyde in
PBS for 12 minutes followed by a 5 minute wash with PBS under centrifugation. Cells were
then permeabilised with 0.1% saponin (Acros Organics) prepared in PBS and stained with
cytokine detection antibodies. Cells were acquired on a Dako Cyan flow cytometer (Dako
Cytomation) and data analysed using FlowJo software (Tree Star). All antibodies were pur-
chased from ebioscience or BD Biosciences and expression quantified relative to the appropri-
ate isotype control.
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Real-time PCR
Total RNA was extracted using the TRIzol method (Life Technologies/Invitrogen). A total of
0.5μg was reverse transcribed with random hexamers using TaqMan reverse transcription
reagents (Life Technologies/Applied Biosystems). Quantitative real-time PCR for VDR and
18SrRNA was then performed on an Applied Biosystems 7900 machine using assays on
demand from Applied Biosystems (18S rRNA, 4319413E; VDR Hs00172113_m1). Amplifica-
tion of cDNAs involved incubation at 50°C for 2 minutes and 95°C for 10 minutes followed by
40 cycles of 95°C for 15 seconds and 60°C for 1 minute. VDR mRNA expression was then cal-
culated relative to 18SrRNA using the delta Ct method.
CD86 acquisition assay (transendocytosis)
A Chinese Hamster Ovarian (CHO) cell line expressing green fluorescent protein-tagged
human CD86 (CD86-GFP) was generated as previously described [15] and cultured in DMEM
(Life Technologies, supplemented with 10% FBS (Biosera), 50U/ml Penicillin and Streptomy-
cin, 200μM glutamine (Life Technologies). Cells were passaged every 3 days. To enable
CD86-GFP to be measured exclusively in T cells at the end of the assay, CHO-cells were
labelled with 5mM Cell Trace Far Red DDAO-SE tracking dye (Molecular probes, Life Tech-
nologies) immediately before use. T cells were prepared by stimulating them for four days with
antiCD3/CD28 Dynabeads beads under Th0 or Th17 conditions in the presence or absence of
1,25(OH)2D3. Beads were removed using a magnet (Easysep StemCell Technologies) and cells
washed with PBS and resuspended in serum free medium (CellGenix). A proportion of T cells
were cultured with anti-CTLA-4 (40μg/ml) for 30 minutes before assembling the T cell-
CHO-CD86GFP co cultures. 50,000 T cells and 150,000 CHO cells were cultured in a 96 well
round bottom plate for 4 hours and 0.5μg/ml anti-CD3 (clone OKT3) added to promote
CTLA-4 cycling. Control wells to set the background CD86-GFP transfer were prepared in
which 5μg/ml anti-CD86 (clone BU63) was included. 30 minutes before analysis, anti-CTLA-
4-PE (BD Biosciences) was added to label cycling CTLA-4. Cells were analysed live by FACS. T
cells were selected by gating according to forward-scatter/side scatter and single cells selected
by pulse width. CHO-cells were excluded by selecting only far-red negative cells. Total CD86
acquisition was calculated by frequency of CD86-GFP+ cells x median fluorescence intensity of
CD86-GFP+ cells. Non CTLA-4-mediated CD86-GFP acquisition, as determined from
aCTLA-4 blocking antibody cultures, was then subtracted.
Dendritic Cell CD80/CD86 downregulation assays
Bead stimulated T cells, polarized for six days under Th0 or Th17 conditions in the presence or
absence of 1,25(OH)2D3, were cell trace violet labelled and a proportion treated with anti-
CTLA-4 (40μg/ml) for 30 minutes before combining with DCs. T cells and DCs were co-cul-
tured overnight in 96 well flat bottom plates at a ratio of 1DC:10 T cells in the presence of
0.5μg/ml anti-CD3 (OKT3). At 24 hours, cells were stained for CD86, CD80, CD11C and
CD40 (BD Biosciences) and analysed by flow cytometry. DCs were selected by scatter and as
violet trace negative.
Suppression assays
T cell suppressors were prepared by stimulating CD4+CD25- T cells with beads for six days.
Beads were removed using a magnet (Easysep StemCell Technologies) and suppressors labelled
with CFDA-SE (Molecular Probes, Life Technologies) as described above. A fraction of the
suppressors were incubated with antiCTLA-4 (40μg/ml) for 30 minutes before the addition of
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autologous DCs and allogenic, unstimulated violet cell trace labelled CD4+CD25- ‘responder’
T cells. Cells were combined at a ratio of 1DC: 40 responders: 8 suppressors and 0.5μg/ml
antiCD3 (OKT3) added. To control for cell number, CFDA-SE labelled unstimulated CD4
+CD25- T cells were used in place of suppressors in control cultures. After 5 days, responder
cell proliferation was monitored by flow cytometry. Single cells were selected according to
pulse width and responder T cells identified as violet trace +ve, CFDA-SE-ve.
Statistical analysis
GraphPad Prism 5.0a software (GraphPad) was used for graphical summary and statistical
analysis was performed using SPSS statistics version 22. Non-parametric Wilcoxon tests were
used to test significance between two conditions when multiple treatments had not been used
and n>5. To test interactions between 1,25(OH)2D3 and cytokine treatments repeated mea-
sures two factor within subject analysis with Huynf-Feldt correction was performed. For mark-
ers that did not show interaction the two factor analysis was re-run in the absence of
interaction. Where interaction was detected single factor repeated measures analysis was per-
formed to determine the effect of cytokine treatment under control and 1,25(OH)2D3 condi-
tions separately. The Shapiro-Wilk normality test and inspection of normal Q-Q plots were
used to confirm that the data could be tested with these parametric models. For data sets that
did not pass the normality test (IL-17, IFNγ and IL-10) the data were log10 transformed, since
by this transformation the residuals from the mean became normally distributed.
Results
Th17 polarising cytokines reduce CTLA-4 expression
To assess the effect of Th17 polarisation on the expression of CTLA-4, we stimulated human
CD4+CD25- T cells with anti-CD3/CD28 beads under Th0 conditions (no added cytokines)
with TGFβ or with the Th17 polarising cytokines, TGFβ, IL-1β, IL-6 and IL-23, as shown (Fig
1a and 1b). Serum free medium was used to avoid background effects of TGFβ. Despite the
absence of serum, the frequency of live cells at the end of culture was 75.4±8.3% and was not
influenced by the cytokine treatment (ANOVA, P = 0.52). Whilst addition of TGFβ alone
strongly induced Foxp3 it did not affect expression of CTLA-4. However, when TGFβ was
combined with the pro-Th17 cytokines, IL-1β, IL-6 and IL-23, which did not affect CTLA-4
without TGFβ (S1 Fig), a significant decrease in CTLA-4 expression was observed (Fig 1). This
was not the result of altered kinetics, since CTLA-4 expression was reduced across all divisions
as defined by cell trace peaks (Fig 1a).
To examine whether loss of CTLA-4 expression was a consequence of the Th17 transcrip-
tional program or a more general phenomenon seen in all T cells exposed to Th17 polarising
cytokines regardless of differentiation status, we measured CTLA-4 expression in relation to
cytokine expression by flow cytometry. CTLA-4 was expressed by approximately 80% of T
cells stimulated under either Th0 or Th17 conditions (Fig 2a) and by the majority of cells that
expressed IL-17 (Fig 2b). Notably Th17 polarising conditions reduced CTLA-4 expression in
CTLA-4+IL-17- as well as CTLA+IL-17+ T cells (Fig 2c), suggesting that the suppressive effect
of Th17 polarising conditions upon CTLA-4 is not limited to cells undergoing the Th17 pro-
gram of differentiation but is a general phenomenon. We explored this further by examining
effects of Th17 polarising cytokines on CTLA-4 expression in T cells defined by the expression
of other pro-inflammatory cytokines or regulatory-associated FoxP3. Th17 polarising cyto-
kines reduced CTLA-4 in cells expressing IFNγ, IL-21, TNFα and IL-2 (Fig 2d) as well as in
FoxP3+ and FoxP3- T cells (Fig 2e). Thus pro-Th17 cytokines suppress CTLA-4 in T cells of
different lineages, both regulatory and inflammatory.
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1,25(OH)2D3 promotes a Treg phenotype and increases CTLA-4
expression even under inflammatory conditions
Given that we have previously demonstrated that 1,25-dihydroxyvitamin D3 (1,25(OH)2D3)
can increase CTLA-4 expression, we next sought to determine if the inhibitory effect of Th17
polarising cytokines on CTLA-4 expression was maintained in the presence of 1,25(OH)2D3.
Fig 1. Th17 polarising cytokines reduce CTLA-4 expression.Cell trace-labelled CD4+CD25- T cells were
stimulated for four days with antiCD3CD28 beads under no cytokine supplement (Th0), with TGFβ alone or
with the pro-Th17 cocktail (TGFβ with IL-1β, IL-6 and IL-23) as indicated and expression of total CTLA-4 and
Foxp3 assessed by flow cytometry. A)Representative FACS plots showing CTLA-4 against Foxp3
expression and cell division, indicated by cell-trace dilution.B) Summary of CTLA-4 expression for 12 donor
donors. Bars indicate mean values and error bars show standard deviation. Significance was tested by
repeated measures, single factor within subject analysis (* = P<0.05, *** = P<0.001).
doi:10.1371/journal.pone.0131539.g001
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CD4+CD25- T cells were therefore stimulated as before under Th0, TGFβ alone and Th17
conditions, either in the presence or absence of 10nM 1,25(OH)2D3. Notably, 1,25(OH)2D3
did not influence the frequency of live cells at the end of culture under any cytokine treat-
ment (PD3>0.05 and PCyt>0.05). However, across cytokine treatments, 1,25(OH)2D3 pro-
moted marked up-regulation of CTLA-4 expression (Fig 3a and S1 Table). Furthermore a
Fig 2. Suppression of CTLA-4 by Th17 polarising cytokines is not specific to IL-17+ T cells.CD4
+CD25- T cells were stimulated in the presence of Th17 polarising cytokines for four days and assessed for
IL-17, IFNγ, IL-21, TNFα, IL-2 or Foxp3 in combination with CTLA-4 by flow cytometry. A) Frequency of total
CTLA-4+ cells.B) Representative bivariate FACS plot of CTLA-4 versus IL-17 for cells cultured under Th17
polarising conditions. C) CTLA-4 expression in CTLA-4+ T cells gated according to IL-17 expression.D)
CTLA-4 expression by CTLA-4+ T cells that expressed IL-17, IFNγ, IL-21, TNFα or IL-2. E) CTLA-4
expression in CTLA-4+ T cells defined by FoxP3 expression. In C, D and E expression under Th17 conditions
is expressed relative to the level under Th0 conditions. Data are summarised for n7 donors. Bars indicate
median values and error bars show the semi interquartile range. Significance with respect to cells expressing
the marker under Th0 conditions was tested byWilcoxon matched paired tests. (* = P<0.05, ** = P<0.01,
*** = P<0.001).
doi:10.1371/journal.pone.0131539.g002
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strong interaction between cytokine treatment and 1,25(OH)2D3 was observed indicating
that the cytokine effect is different when 1,25(OH)2D3 is present. Subsequent inspection
using single factor within subject analysis showed that whilst Th17 conditions suppressed
CTLA-4 in the absence of 1,25(OH)2D3, when 1,25(OH)2D3 was present TGFβ and to a
Fig 3. 1,25(OH)2D3 maintains a regulatory T cell phenotype even under inflammatory, Th17 polarising
conditions. CD4+CD25- T cells were stimulated in the presence of recombinant cytokines IL-1β, IL-6, IL-23
and TGFβ as indicated with or without 1,25(OH)2D3 and expression of regulatory-associated markers CTLA-
4, Foxp3 and CD25 assessed at four days and cytokines IL-2, IL-17, IFNγ, IL-21 and IL-10 measured at five
days by flow cytometry. Data are summarised for n5 donors. Bars indicate mean values and error bars
show the standard deviation. Repeated measures, two factor within subject analysis was used to test
interaction between 1,25(OH)2D3 and cytokine treatment (S1 Table). For markers that did not show
interaction the two factor analysis was re-run in the absence of interaction and P values for each factor are
shown (1,25(OH)2D3 = PD3 and cytokine treatment = PCyt. Where interaction was detected, single factor
analysis was performed. P values are shown for the effect of cytokine treatment under control (Pcyt—D3) and
1,25(OH)2D3 (Pcyt + D3) conditions separately. Significant contrasts between cytokine treatments are
indicated by stars (* = P<0.05, ** = P<0.01, *** = P<0.001).
doi:10.1371/journal.pone.0131539.g003
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greater extent Th17 conditions, enhanced CTLA-4 above the level induced by 1,25(OH)2D3
alone (Fig 3a and S2 Table). In addition to CTLA-4, we analysed the effect of 1,25(OH)2D3
under cytokine treatments upon other markers known to be sensitive to 1,25(OH)2D3,
including FoxP3, CD25, IL-2, IL-17, IFNγ, IL-21, and IL-10 (Fig 3b–3h and S1 and S2
Tables). 1,25(OH)2D3 did not significantly affect the overall expression of FoxP3 or IL-2 but
it did alter the magnitude of the cytokine effects (P interaction <0.05). Nonetheless, in both
the presence and absence of 1,25(OH)2D3 inflammatory cytokines reduced the TGFβ driven
increase of FoxP3 and IL-2. For CD25, 1,25(OH)2D3 significantly increased expression across
treatments but no interaction was detected. By contrast, across all cytokine backgrounds,
1,25(OH)2D3 significantly inhibited IL-17, IFNγ and IL-21 and for IL-17 an interaction
between 1,25(OH)2D3 and cytokine treatment was detected, as 1,25(OH)2D3 reduced the
extent of IL-17 up-regulation by TGFβ and Th17 treatments. For IL-10, which we and others
have previously shown to be induced by 1,25(OH)2D3, we detected a significant effect of 1,25
(OH)2D3 across cytokine treatments as well as a strong interaction. Single factor analysis also
indicated that TGFβ and Th17 conditions strongly suppress IL-10 in the absence of 1,25
(OH)2D3, with Th17 conditions promoting strongest suppression. Under Th0, 1,25(OH)2D3
supressed IL-10. However, in the presence of 1,25(OH)2D3 both TGFβ and Th17 conditions
increased IL-10. Thus, taken together, these data demonstrate that 1,25(OH)2D3 promotes a
regulatory phenotype, with high CTLA-4, and CD25 and lack of inflammatory cytokines
such as IL-17, IFNγ and IL-21. In the presence of TGFβ, FoxP3 was also enhanced and 1,25
(OH)2D3 raised IL-10. Most importantly, our data also show that even when inflammatory
cytokines are present, 1,25(OH)2D3 has the dominant effect and a regulatory T cell pheno-
type is maintained.
Vitamin D receptor expression is increased by TGFβ and maintained in
the presence of Th17 polarising cytokines
Since 1,25(OH)2D3 exerts its effects through the steroidal nuclear vitamin D receptor (VDR),
we investigated the impact of the above treatments on VDR expression. As shown in Fig 4,
TGFβ increased VDR mRNA relative to control. This effect was maintained under Th17 condi-
tions but inflammatory cytokines, IL-1β, IL-6 and IL-23, did not enhance VDR without TGFβ.
Together these data support the hypothesis that increased VDR expression, seen under Th17
conditions, is the result of the influence of TGFβ. Moreover this suggests that the enhanced
effect of 1,25(OH)2D3 on CTLA-4 expression under Th17 conditions, compared with Th0 con-
ditions, may involve increased VDR expression.
1,25(OH)2D3 promotes the suppressive function of CTLA-4 under Th17
conditions
Transendoytosis is the major mechanism via which CTLA-4 mediates T cell suppression.
Thus, having observed that Th17 cytokines suppress CTLA-4, whilst 1,25(OH)2D3 strongly
enhances it, we wished to determine how these treatments affected CTLA-4 trafficking and
transendocytosis. For this, we used an in-vitro system in which Chinese Hamster Ovary (CHO)
cells, stably expressing GFP-tagged CD86, were dye-labelled and co-cultured with CTLA-4
expressing T cell blasts. Anti-CD3 was included to promote T cell activation and stimulate
transendocytosis (Fig 5a). Bivariate flow cytometry analysis of CTLA-4 versus CD86 capture
clearly revealed that capture of CD86 by T cells was related to the level of CTLA-4 trafficking
(Fig 5b). Accordingly, the percentage of T cells that acquired CD86 was reduced under Th17
conditions (P = 0.016, Wilcoxon test n = 7). In contrast, ligand capture was substantially
enhanced in the presence of 1,25(OH)2D3 even under Th17 conditions (Fig 5c). Overall, these
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data reveal that whilst pro-inflammatory Th17 conditions reduce CTLA-4 expression and
therefore transendocytic function, 1,25(OH)2D3 overrides this effect on both expression level
and on transendocytosis, driving a T cell phenotype that has high capacity to remove CTLA-4
co-stimulatory ligands from target cells.
1,25(OH)2D3 enhances CTLA-4-mediated suppression in dendritic cell-
driven stimulations
Although CTLA-4-dependent ligand capture by T cells is an important indicator of suppressive
capability, it does not necessarily reflect the level of ligand downregulation on the APC. Rather,
effective ligand downregulation and therefore suppression ultimately integrates a number of
parameters besides CTLA-4 expression, for example ligand synthesis rates, which could be
influenced by cytokines such as IFNγ and IL-10 [35–37], both of which were modified by 1,25
(OH)2D3 (Fig 3c). With this in mind, we sought to test the significance of altered CTLA-4 lev-
els, as controlled by inflammatory cytokines and 1,25(OH)2D3, upon ligand expression by co-
cultured dendritic cells. T cells were stimulated under Th0 and Th17 conditions in the presence
or absence of 1,25(OH)2D3, and then cultured overnight with DCs. DC expression of CD80,
CD86, and the control markers CD11c and CD40 was then assessed by flow cytometry. As
shown in Fig 6a, all activated T cells caused some downregulation of CD86 and CD80 but not
control proteins. However, the magnitude of CTLA-4-dependent depletion was greatest for T
cells cultured in the presence of 1,25(OH)2D3. Notably, depletion of CD80 was greater than
that of CD86 in line with the higher affinity of CTLA-4 for CD80 [38]. Finally, we tested the
ability of T cells cultured under Th17 and 1,25(OH)2D3 conditions to act as suppressor cells
and affect the proliferation of responder T cells stimulated by DCs. Here we observed that Th0
and Th17 T cells had little effect upon the proliferation of responder T cells, with Th17
Fig 4. Vitamin D receptor (VDR) expression is increased by TGFβ in the presence of Th17 polarising
cytokines. CD4+CD25- T cells were stimulated with antiCD3CD28 antibodies for 18 hours in the presence of
recombinant cytokines and 1,25(OH)2D3 as shown and VDRmRNAmeasured by qPCR. Expression was
normalized to 18S RNA and is plotted relative to expression in the absence of recombinant cytokines or 1,25
(OH)2D3. Data are from four donors. Bars showmedian values and error bars indicate semi interquartile
range.
doi:10.1371/journal.pone.0131539.g004
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conditioned cells showing the least CTLA-4 mediated control. By marked contrast, T cells
stimulated in the presence of 1,25(OH)2D3 under Th17 conditions as well as under Th0 condi-
tions caused robust CTLA-4-mediated suppression (Fig 6b). Taken together, these data sup-
port the view that CTLA-4 on activated T cells plays a role in regulating co-stimulation and
that 1,25(OH)2D3 enhances this pathway. Furthermore, they confirm that the effect of 1,25
(OH)2D3 upon this pathway is maintained, even under inflammatory conditions.
Fig 5. Transendocytic function of CTLA-4 is promoted by 1,25(OH)2D3 andmaintained under
inflammatory conditions. CTLA-4 transendocytic function was tested as described in the methods.A)
Gating strategy to ensure exclusion of CD86-GFP donor cells from the measurement of T cell GFP
acquisition. B) Representative FACS plots of CD86-GFP acquisition versus trafficking CTLA-4.C) Total
CTLA-4 mediated CD86 acquisition by T cells summarized for n = 5 donors. Bars indicate mean values and
error bars show the standard deviation. P values for the separate effects of Th17 cytokines (Pcyt) and 1,25
(OH)2D3 (PD3) are shown as determined by the 2 factor without interaction model since no interaction was
detected (P = 0.146).
doi:10.1371/journal.pone.0131539.g005
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Discussion
A prominent feature of many autoimmune diseases is the inappropriate activation of T cells. T
cell proliferation is initiated following TCR stimulation and supported by engagement of co-
stimulatory CD28 with its ligands CD80 and CD86. Signals through CD28 are important for
initiating and maintaining T cell proliferation, since they can overcome the induction of anergy
[39]. How regulation through the CD28 axis is altered in settings of autoimmunity is therefore
an important area of study. Expression of CTLA-4 is a major mechanism by which Treg cells
elicit tolerance and the levels of CTLA-4 are higher in Foxp3 expressing T cells than in conven-
tional activated T cells [40–42]. Nonetheless, expression of CTLA-4 by activated effector T
Fig 6. 1,25(OH)2D3 promotes CTLA-4-mediated B7 depletion from dendritic cells and suppression of T
cell proliferation. CTLA-4 expressing ‘suppressor cells’ were prepared by stimulating CD4+CD25- T cells
under Th0 or Th17 conditions in the presence or absence of 1,25(OH)2D3. A) Suppressor cells were cultured
with autologous DCs and antiCD3 for 24 hours with or without CTLA-4 blocking antibody. Expression of
CD80, CD86, CD11c and CD40 by DCs was measured by flow cytometry. Dot plots show the ratio of marker
expression in control versus anti-CTLA-4-treated cultures for four donors.B) Suppressor cells were
CFDA-SE labeled and added to autologous DC plus antiCD3 stimulations of allogeneic cell trace violet
labeled CD4+CD25- T cells (responders) with or without anti-CTLA-4. Parallel stimulations were also
prepared in which CFDA-SE-labeled CD4+CD25- were added in place of suppressor T cells as a control for
cell number. At five days, proliferation of responder T cells was assessed by flow cytometry. Data are from
one donor but representative of four. Shaded histograms show proliferation in the absence of suppressors.
Dotted and solid lines indicate proliferation in the presence versus the absence of anti-CTLA-4 respectively.
doi:10.1371/journal.pone.0131539.g006
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cells may also be important for some aspects of immune homeostasis. Indeed, the role of
CTLA-4 in non-Tregs has recently been highlighted by two studies, which reveal a suppressive
capability for activated T cells in-vivo [43, 44]. Altered expression of CTLA-4 by effector T cells
could therefore affect the duration of a T cell response. In line with this, there are differences in
disease kinetics between mice that lack CTLA-4 completely and those where CTLA-4 is defi-
cient only in Treg [42, 45, 46]. In view of these studies it is of interest to understand how
CTLA-4 is regulated.
It is widely recognised that Th17 cells are key players in the development of many inflam-
matory disorders [18–20]. Thus we were interested in how Th17 polarising conditions would
affect CTLA-4 expression and function. We observed that a pro-Th17 cytokine cocktail of
TGFβ, IL-1β, IL-6 and IL-23 reduced CTLA-4 expression in CD4+CD25- T cells after activa-
tion and impaired their ability to remove co-stimulatory ligands by transendocytosis. Notably,
this suppression of CTLA-4 was not restricted to Th17 cells but was evident across T cell classes
including Foxp3+ in-vitro induced Tregs as well as T cells expressing IFNγ, IL-21, TNFα and
IL-2. Thus suppression of CTLA-4 by pro-Th17 cytokines appears a general phenomenon that
is not a consequence of the Th17 differentiation program. Physiologically, inflammation-
driven down-regulation of CTLA-4 might be important to prolong T cell proliferation. Whilst
this effect might be required for the efficient clearance of certain pathogens, down regulation of
CTLA-4 at autoinflammatory sites could contribute to the persistence of the disease. In support
of this hypothesis and our finding that Th17 conditions suppress CTLA-4 in FoxP3+ as well as
FoxP3- T cells, a number of in-vivo studies have reported reduced CTLA-4 expression on
Tregs and non-Tregs from patients with inflammatory disease [47–49]. Most importantly,
their lack of CTLA-4 accounted for their loss of suppressive function [47].
Epidemiological studies suggest an inverse relationship between vitamin D status and the
incidence of autoimmune diseases (reviewed in [25, 26, 29]). The significance of vitamin D in
immune regulation is supported by the fact that immune cells, especially antigen presenting
cells, express the enzyme 1α-hydroxylase that is necessary for vitamin D activation [50–53].
Indeed we have shown that activated T cells can induce 1α-hydroxylase activity in DCs at a
level sufficient to influence the T cell response [51]. It has long been considered that the princi-
pal mechanism by which 1,25(OH)2D3 suppresses T cell responses is by down-regulating
MHC and co-stimulatory molecules on APCs [54–56]. However, our previous finding that
1,25(OH)2D3 increases CTLA-4 through direct effects upon the T cell, suggested that the sup-
pressive effect of 1,25(OH)2D3 upon T cell activation might be further enhanced through
CTLA-4-mediated removal of CD80/86 by transendocytosis. Through this study we have con-
firmed that by increasing CTLA-4, 1,25(OH)2D3 can increase transendocytic removal of
CD80/86 from APCs and substantially reduce their ability to stimulate T cells. Thus, 1,25
(OH)2D3 appears to target both the APC and T cell sides of the CD80/CD86-CD28/CTLA-4
axis to achieve maximal suppression of T cell responses. Importantly we have also shown that
this ability of 1,25(OH)2D3 to increase CTLA-4 expression and transendocytic function is
retained, if not enhanced, under Th17 polarising conditions. Taken together these data suggest
that low levels of vitamin D might predispose to exaggerated inflammatory reactions along
with impaired CTLA-4 expression and that provision of 1,25(OH)2D3 would reverse this effect
even at sites of active Th17-driven inflammation.
Many chronic inflammatory diseases develop as a consequence of exposure to environmen-
tal triggers in a genetically susceptible individual. Interestingly, a number of polymorphisms
associated with chronic inflammatory diseases lie within the co-stimulation gene locus at chro-
mosome 2q33 that encodes CD28, CTLA-4 and ICOS [57–61] and ChIP-seq studies have
revealed the presence of VDR binding sites near to these polymorphisms [62]. Thus regulation
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of CTLA-4 expression could be a point at which genetic and environmental factors interact to
influence an immune response and the establishment of disease.
Overall, our study has provided new insights into the regulation of CTLA-4, a critical sup-
pressive protein whose loss of function is associated with autoimmunity. In particular we have
shown that inflammatory Th17 conditions, suppress the expression and transendocytic func-
tion of CTLA-4, but demonstrate that their effect can be opposed by 1,25(OH)2D3. In addition,
we confirmed that the ability of 1,25(OH)2D3 to suppress inflammatory cytokines and increase
IL-10 was retained even under inflammatory conditions. Our findings therefore highlight a
potential role for vitamin D as an environmental factor in the control of autoimmunity and
support the exploration of its use as a therapeutic agent for established disease as well as in
prophylaxis.
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